Hypertension – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Hypertension Market Outlook

Thelansis’s “Hypertension Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypertension treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hypertension Overview

Hypertension, characterized by a systolic blood pressure (BP) of ≥130 mm Hg or a diastolic BP of ≥80 mm Hg, or the use of antihypertensive medication, is prevalent among adults in the United States, with almost half of the population affected. Although approximately 80% of adults with hypertension are advised to undergo treatment involving medication and lifestyle modifications, only about half of them receive such treatment. Blood pressure tends to rise with age, with around two-thirds of individuals over 65 years old affected by hypertension. Furthermore, individuals with normal BP at age 55 face a substantial lifetime risk of developing hypertension. Despite its common occurrence in older age groups, elevated blood pressure poses significant health risks, including increased morbidity and mortality. The American College of Cardiology/American Heart Association (ACC/AHA) classifies blood pressure in adults into normal, elevated BP, and stages 1 and 2 hypertension. Notably, blood pressure norms for infants and adolescents differ significantly from those of adults. Symptoms of hypertension are typically absent until complications arise in target organs, and common symptoms such as dizziness, flushing, and headaches are not directly caused by uncomplicated hypertension. Severe hypertension, defined by a systolic BP of ≥180 mm Hg and a diastolic BP of ≥120 mm Hg, may manifest as either asymptomatic hypertensive urgency or as a hypertensive emergency with severe cardiovascular, neurologic, renal, and retinal symptoms. The formal diagnosis of hypertension requires an average of 2 or 3 measurements taken at different times under specific conditions, including a seated position, no recent exercise, caffeine, or smoking, and with the limb supported at heart level and the cuff placed without clothing obstruction. While primary hypertension lacks a cure, secondary hypertension may be corrected by addressing underlying causes. Regardless of etiology, controlling blood pressure is crucial in mitigating adverse outcomes. The selection of antihypertensive medication depends on various factors, including comorbidities and contraindications. Initial monotherapy may involve medications such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), dihydropyridine calcium channel blockers, or thiazide diuretics, preferably thiazide-like diuretics like chlorthalidone or indapamide.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: